NCT06038318 Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer
| NCT ID | NCT06038318 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Stress |
| Study Type | INTERVENTIONAL |
| Enrollment | 325 participants |
| Start Date | 2023-10-16 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 325 participants in total. It began in 2023-10-16 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to find the best way to help participants and families manage the stress of facing a serious illness and be better able to "bounce back" or be resilient after a difficult situation. Participants will take part in the "Promoting Resilience in Stress Management" PRISM program, which is designed to provide skills to change or improve the impact of stress in everyday life. The name of the intervention used in this research study is: -PRISM (a mobile app program comprised of 6 sessions of skills-based, manualized resilience education)
Eligibility Criteria
Participants that have completed their main cancer-directed therapy at one of the study sites affiliated centers who meet all the eligibility criteria will be eligible for participation in this study. Inclusion Criteria: * All genders ≥ 12 and ≤ 25 years of age at baseline * Participant is able to speak English or Spanish language (for PRISM sessions) * Participant is able to read English or Spanish language (for completion of surveys) * Participant is cognitively able to participate in PRISM sessions and complete written questionnaires and surveys, as judged by the site investigator
Contact & Investigator
Abby Rosenberg, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06038318 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 25 Years, studying Stress. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06038318 currently recruiting?
Yes, NCT06038318 is actively recruiting participants. Contact the research team at AbbyR_Rosenberg@DFCI.HARVARD.EDU for enrollment information.
Where is the NCT06038318 trial being conducted?
This trial is being conducted at Boston, United States, Boston, United States.
Who is sponsoring the NCT06038318 clinical trial?
NCT06038318 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Abby Rosenberg, MD at Dana-Farber Cancer Institute. The trial plans to enroll 325 participants.